DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Follow-Up Questions
What is Dbv Technologies SA (DBVT)'s P/E Ratio?
The P/E ratio of Dbv Technologies SA is N/A
Who is the CEO of Dbv Technologies SA?
Mr. Daniel Tasse is the Chief Executive Officer of Dbv Technologies SA, joining the firm since 2018.
What is the price performance of DBVT stock?
The current price of DBVT is 9.6, it has increased 0.13% in the last trading day.
What are the primary business themes or industries for Dbv Technologies SA?
Dbv Technologies SA belongs to Biotechnology industry and the sector is Health Care
What is Dbv Technologies SA market cap?
Dbv Technologies SA's current market cap is $262.6
Is Dbv Technologies SA a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Dbv Technologies SA, including 3 strong buy, 3 buy, 1 hold, 1 sell, and 3 strong sell
